Thank you, Matt, and good morning, everybody. We'll start with EPS. First quarter adjusted EPS was $0.85, up 2.4% the prior year. The $0.85 was better than our $0.75 outlook, primarily due to continued strong consumer demand for many of our products, and higher-than-expected gross margins. Reported revenue was up 10.2% and organic sales were up 5.7%. About half of the reported revenue growth year-over-year was HERO. Organic sales were once again driven by pricing in Q1. However, as Matt mentioned, the fact that volume was flat, was encouraging and gives us confidence that we will return to volume growth later this year. Matt covered the segments, so I'll go right into gross margin. Our first quarter gross margin was 43.5%, a 90 basis point increase from a year ago, primarily due to improved pricing, productivity and the impact of the HERO acquisition, net of the impact of higher manufacturing costs. Let me walk you through the Q1 bridge. Gross margin was made up of the following: positive 160 basis points impact from price/volume mix, positive 120 basis points from acquisitions, a positive 160 basis points from productivity and 10 basis points from currency, partially offset by a drag of a 360 basis point impact due to higher manufacturing costs, including inventory charges related to discretionary brands primarily flawless. For the balance of the year, we still expect sequential improvement in gross margin year-over-year expansion throughout the year. Moving to marketing. Marketing was up $20 million year-over-year. Marketing expense as a percentage of net sales was 8.6% or 70 basis points higher than Q1 of last year. For SG&A, Q1 adjusted SG&A increased 90 basis points year-over-year. Other expense all-in was $23 million, an $8.6 million increase due to higher interest rates. Our expectations for interest rates for the remainder of the year remain unchanged from our prior guidance. We do not have any looming long-term debt refinancings. In fact, August of 2027 is the timing of our next maturity. For income tax, our effective rate for the quarter was 24.4% compared to 23.2% in 2022, an increase of 120 basis points. We continue to expect the full year rate to be approximately 23%. And now to cash. For the first three months of 2023, cash from operating activities increased to $273 million due to higher cash earnings and improvements in working capital. We now expect full year cash flow from operations to be approximately $950 million. Previously, we expected $925 million. The $25 million increase is driven by higher cash earnings and an improvement in working capital. Our full year CapEx plan continues to be approximately $250 million as we continue to make capacity investments, and we expect to return to historical levels by 2025. And now for the full year outlook. Given the strength of our Q1 results and our confidence for the remainder of the year, we are raising our outlook for sales, EPS, gross margin and cash flow. We now expect the full year 2023 reported sales growth to be approximately 6% to 7% and organic sales growth to be approximately 3% to 4%. We now expect full year EPS in the range of 2% to 4% growth. Given the strength of the business, we see opportunities to make incremental investments in our brands and capabilities in future quarters. We now expect full year reported gross margin to expand approximately 120 basis points. And as we expect pricing and productivity to more than offset inflation. Our full year inflation expectations remain unchanged from our previous outlook. Gross margin is expected to benefit from pricing, pack size changes, longer concentration and the full year impact of the higher-margin HERO business. As you read in the release, two items of note that are aiding our margin recovery are new litter pricing that went into effect on February 1 and the latest round of concentration for laundry. We intend to increase marketing as a percent of net sales to 10.5%. We continue to expect SG&A both in dollars and as a percent of net sales to increase compared to 2022 as the company's incentive compensation plan returns to normal levels in 2023. As a reminder, our EPS guidance includes a step-up in our level of marketing investment as well as higher SG&A. For Q2, we have a strong outlook and expect reported sales growth of approximately 7%, organic sales growth of approximately 3% and gross margin expansion and higher marketing spending. The math would show a sequential decline in sales growth, but it's easy to explain. First, distribution pipeline fill for HERO and THERABREATH accounted for 1% of growth in Q1 that will not repeat in Q2. The other is around quarterly comps and how that impacts the current year. For the domestic business, there was a large improvement in case fill in Q1 to Q2 last year, which leads to a tougher comp in Q2 of this year compared to Q1 last year. As an example, our international business in Q1 in 2022, organic growth was 0 and in Q2 it was 6.5% in 2022. As a result, adjusted EPS is expected to be $0.78 per share, a 2.6% increase from last year's adjusted Q2 EPS. And with that, Matt and I would be happy to take questions.